Gene therapy for nearsighted vision loss from wet AMD
Part of Eyes & vision clinical trials.
This Phase 1 study tests a gene therapy treatment for wet age-related macular degeneration (wet AMD) to see if it can help vision. You may qualify if you’re 45 or older with wet AMD that is active and your current vision is below a certain level.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be willing and able to follow all study visit and procedure instructions
- Be age 45 or older when you sign the consent form
- Have a confirmed diagnosis of wet AMD (nAMD)
- Have active abnormal blood vessel growth (CNV) in the study eye
- Your best corrected vision in the study eye must be 53 letters or worse (with your current glasses/contacts)
- You should not have any other eye conditions in the study eye that could affect vision or require treatment during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy, FT-003, for people with wet AMD. It aims to see if a single treatment can help stop vision loss and may reduce the need for frequent eye injections.
This trial tests a new gene therapy called RRG001 for people with the 'wet' form of age-related macular degeneration. It aims to treat leaky blood vessels in the eye that can cause vision loss, possibly reducing the need for frequent eye injections.
This study tests a new gene therapy injection called SKG0106 for people with wet AMD. The treatment is given as an injection into the eye and aims to reduce the need for frequent anti-VEGF shots.
This trial tests a new gene therapy (LX111) for people with wet age-related macular degeneration (AMD) who have already been helped by standard anti-VEGF injections. The goal is to see if one dose of LX111 can reduce the need for frequent eye injections.
This trial tests a one-time gene therapy injection under the retina for people with wet age-related macular degeneration (AMD), which causes blurry vision from abnormal blood vessels. It aims to reduce the need for frequent eye injections by delivering a treatment that may help the eye produce its own medicine.
This trial tests a gene therapy (KH658) as a one-time treatment for wet macular degeneration. It's for people whose condition has been stabilized with anti-VEGF injections, and aims to see if it is safe and can reduce the need for frequent eye injections.
Hear when a new Neovascular Age-related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.